Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene

Rationale:Meconium ileus (MI) is a perinatal complication in cystic fibrosis (CF), which is only minimally influenced by environmental factors. We derived and examined MI prevalence (MIP) scores to assess CFTR phenotype–phenotype correlation for severe mutations.Method:MIP scores were established using a Canadian CF population (n = 2,492) as estimates of the proportion of patients with MI among all patients carrying the same CFTR mutation, focusing on patients with p.F508del as the second allele. Comparisons were made to the registries from the US CF Foundation (n = 43,432), Italy (Veneto/Trentino/Alto Adige regions) (n = 1,788), and Germany (n = 3,596).Results:The prevalence of MI varied among the different registries (13–21%). MI was predominantly prevalent in patients with pancreatic insufficiency carrying “severe” CFTR mutations. In this severe spectrum MIP scores further distinguished between mutation types, for example, G542X (0.31) with a high, F508del (0.22) with a moderate, and G551D (0.08) with a low MIP score. Higher MIP scores were associated with more severe clinical phenotypes, such as a lower forced expiratory volume in 1 second (P = 0.01) and body mass index z score (P = 0.04).Conclusions:MIP scores can be used to rank CFTR mutations according to their clinical severity and provide a means to expand delineation of CF phenotypes.Genet Med 18 4, 333–340.

[1]  Michael R Knowles,et al.  Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis , 2012, Nature Genetics.

[2]  B. Kerem,et al.  Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. , 1992, American journal of human genetics.

[3]  Rory L. Michaelis,et al.  Lung function decline from adolescence to young adulthood in cystic fibrosis , 2012, Pediatric pulmonology.

[4]  M. Corey,et al.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas , 2003, Gut.

[5]  V. Raia,et al.  Growth Assessment of Paediatric Patients With CF Comparing Different Auxologic Indicators: A Multicentre Italian Study , 2009, Journal of pediatric gastroenterology and nutrition.

[6]  S. Raudenbush,et al.  Application of Hierarchical Linear Models to Assessing Change , 1987 .

[7]  M. Corey,et al.  Cystic fibrosis patients bearing both the common missense mutation Gly----Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. , 1992, American journal of human genetics.

[8]  M. Corey,et al.  Genetic determination of exocrine pancreatic function in cystic fibrosis. , 1992, American journal of human genetics.

[9]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[10]  David Wypij,et al.  Pulmonary function between 6 and 18 years of age , 1993, Pediatric pulmonology.

[11]  Anthony S. Bryk,et al.  Application of Hierarchical Linear Models to Assessing Change , 1987 .

[12]  M. Corey,et al.  Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13 , 1999, Nature Genetics.

[13]  D Markiewicz,et al.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). , 1990, The New England journal of medicine.

[14]  M. Kosorok,et al.  Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. , 2004, American journal of epidemiology.

[15]  M. Drumm,et al.  Variation in MSRA Modifies Risk of Neonatal Intestinal Obstruction in Cystic Fibrosis , 2012, PLoS genetics.

[16]  M. Corey,et al.  Do common in silico tools predict the clinical consequences of amino‐acid substitutions in the CFTR gene? , 2010, Clinical genetics.

[17]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[18]  L. Lagasse,et al.  Methamphetamine and Other Substance Use During Pregnancy: Preliminary Estimates From the Infant Development, Environment, and Lifestyle (IDEAL) Study , 2006, Maternal and Child Health Journal.

[19]  S. Philcox.  Type of CFTR Mutation Determines Risk of Pancreatitis in Patients With Cystic Fibrosis , 2011 .

[20]  U. Wahn,et al.  Pancreatic insufficiency and pulmonary disease in German and Slavic cystic fibrosis patients with the R347P mutation , 1995, Human mutation.

[21]  A. Curtis,et al.  GENETIC DIFFERENCES BETWEEN CYSTIC FIBROSIS WITH AND WITHOUT MECONIUM ILEUS , 1989, The Lancet.

[22]  L. Hjelte,et al.  Association between genotype and pulmonary phenotype in cystic fibrosis patients with severe mutations. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[23]  D. Vilozni,et al.  Meconium Ileus in Patients With Cystic Fibrosis Is Not a Risk Factor for Clinical Deterioration and Survival: The Israeli Multicenter Study , 2010, Journal of pediatric gastroenterology and nutrition.

[24]  Y. Sohma,et al.  G551D and G1349D, Two CF-associated Mutations in the Signature Sequences of CFTR, Exhibit Distinct Gating Defects , 2007, The Journal of general physiology.

[25]  David K Meyerholz,et al.  Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. , 2010, The Journal of clinical investigation.

[26]  B. Kerem,et al.  Correlation between genotype and phenotype in patients with cystic fibrosis. , 1994, The New England journal of medicine.

[27]  V. Raia,et al.  Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[28]  A. Chakravarti,et al.  Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. , 2006, Gastroenterology.

[29]  G. Cutting,et al.  Two cystic fibrosis transmembrane conductance regulator mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Feingold,et al.  Genetic comparisons of patients with cystic fibrosis with or without meconium ileus. Clinical Centers of the French CF Registry. , 1999, Annales de genetique.

[31]  M. Corey,et al.  Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. , 1989, The Journal of pediatrics.

[32]  C. Boeck.  Correlation between genotype and phenotype in patients with cystic fibrosis , 1993 .

[33]  M. Corey,et al.  Understanding the population structure of North American patients with cystic fibrosis , 2011, Clinical genetics.

[34]  G. Cutting,et al.  Genetic modifiers of nutritional status in cystic fibrosis. , 2012, The American journal of clinical nutrition.

[35]  E. Hoffman,et al.  Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. , 2013, The Journal of clinical investigation.

[36]  M. Amaral,et al.  CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. , 2004, Gastroenterology.

[37]  L. Lagasse,et al.  New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates. , 2010, Clinical chemistry.

[38]  Theodore Chiang,et al.  Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities , 2013, Human Genetics.

[39]  S. McColley,et al.  Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis , 2012, Pediatric pulmonology.

[40]  D. Borowitz,et al.  A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. , 2012, Journal of pediatric surgery.

[41]  K. Klinger,et al.  Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population. , 1993, American journal of human genetics.

[42]  C. Bear,et al.  Direct Interaction Of A Small Molecule Modulator With G551D-CFTR, A Cystic Fibrosis Causing Mutation Associated With Severe Disease , 2009 .

[43]  F. van Goor,et al.  Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[44]  George P Patrinos,et al.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.